LSTA
LISATA THERAPEUTICS, INC.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 6 Lisata Therapeutics (LSTA) has agreed to be acquired by private comp…
- A May 15 HC Wainwright & Co. downgrades
- X Aug 31 Short interest jumps 57.8% to 141.8K
- E Sep 17 Trading halt: Trading Halt: LSTA — T1 (News Pending)
- R Sep 17 Lisata Therapeutics (LSTA) has completed its acquisition of Marea Th…
- R Sep 17 Lisata Therapeutics acquires Marea Therapeutics in a stock-for-stock…
- X Sep 30 Short interest falls 76.1% to 39.4K
- R Oct 19 Lisata Therapeutics is holding a special annual meeting to seek stoc…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 2 trimmed or exited.
- TrendDOWNTREND
29% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| ROYAL BANK OF CANADA | NEAR_EXIT | — |
| VANGUARD FIDUCIARY TRUST CO | ADD | $166.5K |
| CITADEL ADVISORS LLC | TRIM | $52.8K |
| NORTHERN TRUST CORP | ADD | $52.8K |
| STATE STREET CORP | ADD | $127.0K |
| UBS Group AG | DOUBLED | $9.6K |
| OSAIC HOLDINGS, INC. | DOUBLED | $1.0K |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $26.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action May 2026Price is below the lowest target. Median implies +300%.Targets as of Jul 20, 2026.
| Date | Firm | Rating |
|---|---|---|
| May 15, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | -$1.09 | -$1.09–-$1.09 | -13.5% | $0.00 |
| Next FY | -$1.16 | -$1.16–-$1.16 | -75.8% | $0.00 |
Short side
FINRA· Oct 15, 2026| Sep 17, 2026 | Resumption Scheduled | Resumed |
SecBot reports
10 filings · 3 press releases · 1 bullish · 6 bearish · 1 mixed · 2 neutral- BEARISH DEF 14AOct 19, 2026
Lisata Therapeutics is holding a special annual meeting to seek stockholder approval for proposals…
The November 9 vote is binary: approval unlocks the Marea reverse merger and Nasdaq listing; failure triggers cash settlement risk and potential delisting. Monitor proxy solicitation results…
- NEUTRAL 8-KOct 14, 2026
Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors, filling a newly created…
Routine board addition with no immediate financial catalyst. Monitor upcoming Phase 2b data readouts for MAR001 (severe hypertriglyceridemia) and MAR002 (acromegaly) as the primary value drivers.
- BULLISH 8-KSep 17, 2026
Lisata Therapeutics (LSTA) has completed its acquisition of Marea Therapeutics via a reverse…
The merger and PIPE transform LSTA's balance sheet and pipeline. The key catalyst is the upcoming stockholder vote to approve the conversion of the Series C Preferred Stock, which is required for…
- BULLISH PRESS RELEASESep 17, 2026
Lisata Therapeutics acquires Marea Therapeutics in a stock-for-stock transaction and concurrently…
The near-total dilution of legacy Lisata shareholders (~2.39% ownership) and pivot to Marea's cardioendocrine pipeline make this a de facto reverse merger. Watch for stockholder vote on Series C…
All LSTA filing & press-release reports (13)
- DEF 14A reportOct 19, 2026
- 8-K reportOct 14, 2026
- 8-K reportSep 17, 2026
- PRESS-RELEASE reportSep 17, 2026
- 8-K reportAug 4, 2026
- 8-K reportJul 24, 2026
- 8-K reportJul 17, 2026
- PRESS-RELEASE reportJun 10, 2026
- 8-K reportJun 9, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 29, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 6, 2026